Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients
with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard
treatment" for this unusual group of patients who are not usually eligible for clinical
trials.